Darolutamide Demonstrates Strong Safety Profile in mCRPC after Long-Term Analyses - OncLive

Retrieved on: 2022-02-19 05:54:14

Tags for this article:

Click the tags to see associated articles and topics

Darolutamide Demonstrates Strong Safety Profile in mCRPC after Long-Term Analyses - OncLive. View article details on hiswai:

Excerpt

Heinz-Josef Lenz, MD, discusses the safety and efficacy of nivolumab plus standard of care in patients with metastatic colorectal cancer, shares ...

Article found on: www.onclive.com